🚨 BREAKING News from Clival Database!| WEEK 2 | 11th July 2026 🚨 Pharma Trial News: Lynk Begins Phase 2 | Keenova Achieves Phase 3 Milestone 🚀 🔹 Lynk Pharmaceuticals doses first patient in phase II trial of LNK01004 ointment for vitiligo 🔹 Keenova Therapeutics announces positive results from phase 3 trial of Xiaflex for the treatment of plantar fibromatosis 🚀 These breakthroughs highlight how innovation, advanced clinical strategies, and global expansion are reshaping the future of healthcare and patient outcomes. 🎥 Watch complete analysis & expert insights on our YouTube channel: 👉 https://lnkd.in/g655VA-J 📰 Explore more verified clinical and pharma updates anytime: 👉 https://clival.com/news 📊 Want deeper clinical intelligence, pipeline tracking, competitor benchmarking, and real-time pharma insights? 📅 Book a demo with Clival Database today: 👉 https://lnkd.in/dSdbxTJF 📡 Daily updates. Verified insights. Real-time research breakthroughs — only on Clival Database. 🌐 Visit: www.clival.com 📞 Toll-Free: 1800 4190 155 #Clival #ClivalDatabase #ClinicalResearch #PharmaNews #BiotechNews #ClinicalTrials #MedicalResearch #PharmaInnovation #BiotechInnovation #LifeSciences #DrugDevelopment #HealthcareInnovation #PharmaTrends #LifeScienceIntellipedia

Physicians value market research, but that doesn't mean every study feels equally worth their time. In our latest MD Analytics independent study among 150 US physicians, 95% agreed that market research is an important way to share their perspectives with the pharmaceutical industry. At the same time, participation is shaped by format, flexibility, topic relevance, incentive structure, and ease of working with the research provider. That distinction matters! For teams planning physician research, the question may not be whether physicians are open to participating. It may be whether the study is designed around what makes participation feel realistic. If you would like to see the full findings, we would be happy to present them live and discuss what they may mean for your team. MD Analytics is a full-service healthcare-focused primary market research agency.

Camlipixant, which GSK picked up in its $2 billion buyout of Bellus Health in April 2023, “is unlikely to transform patient care,” the pharma said. https://hubs.li/Q04pS5MS0

Drug development isn't just about moving forward—it's also about knowing when to change direction. In clinical research, every trial outcome helps shape the next decision. Sometimes, a setback doesn't end a strategy—it refines it. That's exactly what happened with Agios Pharmaceuticals' tebapivat. After the investigational PK activator fell short in a Phase 2 sickle cell disease (SCD) trial, the company shifted its focus to mitapivat, another PK activator with a stronger evidence base and ongoing late-stage development. 🔗 Read the full article: https://lnkd.in/egRG-63J One unsuccessful trial doesn't define a therapeutic approach—it often helps identify the most promising path forward. #MedicalWriting #ClinicalResearch #SickleCellDisease #DrugDevelopment #ClinicalTrials #MedicalJournalism #EvidenceBasedMedicine #PharmD #Pharmacally

🚀 Pharma & Healthcare News | July 25, 2026 From EU approvals, FDA Fast Track designations, AI-powered clinical platforms, and oncology breakthroughs to cold-chain innovations and supply chain investments, today's updates reflect the rapid pace of transformation across the global pharmaceutical industry. Stay informed. Stay compliant. Stay ahead. #Pharma #Healthcare #ClinicalResearch #Biotech #RegulatoryAffairs #DrugDevelopment #FDA #EMA #Oncology #AIInHealthcare #MedicalDevices #PharmaNews #PharmaWithSahil

The MHRA's approval of 47 new medicines in 2026 carries important implications for clinicians, patients, and healthcare commissioners. First, these authorisations reflect a thriving pharmaceutical innovation pipeline, signalling that the UK regulatory system continues to facilitate patient access to emerging therapies across multiple disease areas. https://lnkd.in/dNN7dRed

Reta just put up 30% weight loss in a Phase 3 trial. Semaglutide started this whole thing at 15%. Topline results from Eli Lilly's TRIUMPH-1 study showed the triple agonist producing up to 30% weight loss over 104 weeks, according to the Pharmaceutical Journal. Tirzepatide sits at around 21%. Semaglutide started the category at roughly 15%. Here's the part that doesn't show up in the trial data: Every time that number climbs, it resets what patients expect their own results to look like, even the ones already mid protocol on an older drug. Someone who lost 18% of their body weight on tirzepatide felt great about that a year ago. Now there's a headline saying a different drug got someone else to 30%, and suddenly 18% can start to feel like they got the lesser version instead of a legitimate result. It's an expectation problem, not a science problem, and it's going to land on whoever is running that patient's protocol, not on Eli Lilly's trial data. Clinics that get ahead of it by talking honestly about individual response and why the newest drug isn't automatically the right one for everybody are going to have an easier time holding onto patients than the ones who let the headlines set the conversation for them.

The projected growth of the global Clinical Trial Services market highlights the increasing investment in bringing innovative therapies to patients faster. Beyond the numbers, one factor is essential for every successful clinical trial: operational excellence. From clinical supply logistics and inventory management to regulatory compliance, data integrity, and cross-functional collaboration, efficient operations play a critical role in ensuring studies run smoothly and reliably. As our industry continues to grow, strengthening operational processes and fostering a culture of continuous improvement will be just as important as scientific innovation. Innovation doesn't happen only in the lab—it also happens every day in the operations that make clinical research possible. #ClinicalTrials #ClinicalResearch #ClinicalSupplyChain #ClinicalLogistics #Operations #SupplyChain #DataIntegrity #ContinuousImprovement #LifeSciences

Interesting overview of the global CRO giants. It’s worth remembering that the Davids in the ecosystem don’t just challenge scale — they complement it. Focused, disciplined operators often provide the accuracy and reliability that make large‑scale execution possible. A very insightful and valuable insight from GCP shared below:

📰 In the latest issue of Pharma & Health Business: A special feature on oncology and the challenges of modern healthcare. 🔎 In the new issue, you’ll read: ♦️ A digital leap forward for Greece ♦️ The value of pharmaceutical innovation ♦️ Uncertainty regarding Greeks’ access to innovation ♦️ The global cancer crisis ✨ Don’t miss it! All the latest developments in the pharmaceutical market and healthcare in the new issue of Pharma & Health Business. 📖 Learn more about the FULL PACK or DIGI PACK subscriptions: https://lnkd.in/d6B2457a Virus.com.gr  LiveOn #health #pharma #esg #csr #pharmaceuticals #healthcare #patients #corporate #magazine